Skip to main content

Table 1 Summary of patient data

From: Effect of polypharmacy on plasma bepridil concentration in patients with heart failure: a multicenter retrospective study

Factors

n = 359

Sex (Male/Female)

238/121

Age (years)

71 (64, 79)d

Height (m)

1.64 (1.55, 1.71)d

Body weight (kg)

62.55 (54.68, 72.40)d

Body mass index (kg/m2)

23.41 (21.15, 25.65)d

Serum creatinine (mg/dL)

0.88 (0.74, 1.03)d

Ccr (mL/min)

64.63 (47.56, 86.03)d

Daily dose of bepridil (mg/kg body weight)

1.58 (1.24, 2.02)d

Period of bepridil treatment (day)

356 (124, 1404)d

Plasma bepridil concentration (ng/mL)

300 (157, 491)d

C/D ratio of bepridil (ng/mL) / (mg/day/kg)

186 (108, 278)

LVEF (%)

65.1 (59.1, 69.9)d

 HFrEFa, n (%)

14 (3.9)

 HFmrEFb, n (%)

28 (7.8)

 HFpEFc, n (%)

317 (88.3)

Patient’s medical history, n (%)

 Coronary artery bypass graft

3 (0.8)

 Graft replacement

1 (0.3)

 Atrial fibrillation

346 (94.3)

 Heart valve replacement or formation

8 (2.2)

Concomitant drugs for HF and comorbidities, n (%)

 ACE inhibitor/ARB

116 (32.3)

 β-blocker

218 (60.7)

 Calcium-channel blocker

98 (27.3)

 Statins

111 (30.9)

 Diuretics

89 (24.8)

 Antidiabetic drugs

40 (11.1)

 Anticoagulant drugs

286 (79.7)

  1. ACE Angiotensin converting enzyme, ARB Angiotensin II receptor blocker, Ccr Creatinine clearance, C/D Concentration-to-dose, HFmrEF Heart failure with mid-range ejection fraction; HFpEF Heart failure with preserved ejection fraction, HFrEF Heart failure with reduced ejection fraction, LVEF Left ventricular ejection fraction
  2. aLVEF< 40%
  3. b40%≦LVEF< 50%
  4. C50%≦LVEF
  5. dEach value represents the median (25 to 75% percentile)